Prime Medicine (PRME)
Develops Prime Editing therapies for liver, lung, and partnered cell-therapy programs.
$3.49
After hours−0.05 (−1.50%)
At close$3.55(+11.13%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 59.31% | 107.58M shares | |
|---|---|---|---|
| 195 holders · as of Jun 30, 2026 | |||
| Insiders | 23.74% | 43.07M shares | |
| 7 holders · as of Aug 11, 2025 | |||
| Other | 16.95% | 30.73M shares | |
| remainder | |||
181.38M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
195 holders · 107.58M shares · 24 new positions · 87 increased · 69 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Alphabet Inc. | 16.56M | 9.13% | 0 | Aug 7, 2026 |
| BlackRock, Inc. | 9.60M | 5.29% | +1.10M | Aug 7, 2026 |
| Ark Investment Management LLC | 8.35M | 4.60% | +2.10M | Aug 14, 2026 |
| State Street Corp | 7.58M | 4.18% | +1.23M | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.24M | 2.89% | −244.6K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.52M | 2.49% | +48.5K | Aug 13, 2026 |
| Balyasny Asset Management L.P. | 3.97M | 2.19% | −154.3K | Aug 14, 2026 |
| Goldman Sachs Group Inc | 3.43M | 1.89% | +2.46M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Robert Nelsenincl. ARCH Venture Fund XII, L.P., Steven Gillis +9 more | 10.40% | 18.59M | 13D | Aug 11, 2025 |
| Bristol-Myers Squibb Company | 8.40% | 11.01M | 13G | Oct 4, 2024 |
| GV 2019, L.P. | 7.50% | 10.10M | 13G | Nov 12, 2025 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.